Breast density, which is increasingly used as a marker of breast cancer risk, is associated with the use of multivitamins, a new study shows.
This study was designed to evaluate the expression of B7-H4 precentlyrecently identified as a potential molecular marker of breast and ovarian cancer by quantitative PCR analysis, in benign tumors, tumors of low malignant potential and malignant tumors of the ovary.
These results suggest MIIP K167E as a functional genetic marker of breast cancer development and prognosis.
The GCDFP-15 used in our case is also a specific marker of breast cancer [6].
ERBB2 expression constitutes a well known marker of breast tumors aggressiveness and its overexpression is associated with a worse prognostic and reduced survival [31].
Also, DDB2 may represent an important clinical interest as a prognostic/predictive marker of breast cancer progression towards an aggressive phenotype.
These data show that Hh pathway activation is linked to Wnt-1-induced mammary tumor onset and nevi formation and suggest that Hedgehog pathway activation maybe a critical component and useful marker of breast tumors arising from unopposed Wnt1 ligand.
As the inactivation of ErbB receptors is a new tool in cancer treatment, future studies could lead to the development of hMena overexpression as a marker of breast cancer progression.
Hence, SCCA expression may be indicative of breast SCC and has the potential to be a valuable marker of breast SCC, as well as predicting disease severity and response to treatment as has been demonstrated in other SCCs.
Recently, we have demonstrated that hMena overexpression represents an early marker of breast tumorigenesis, being undetectable in normal breast epithelium, and overexpressed in benign breast lesions with an increased risk of transformation and, in more than 70% of tumors, with HER2+, ER/PgR- and high Ki67 phenotype [15].
The prints can thus represent a noninvasive anatomical marker of breast cancer risk [ 4- 6].
